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Introduction: Blood and marrow transplantation is a low
volume, high risk specialty. Institutional practices vary
considerably. Consensus practice is important for physician
and family conﬁdence and to optimize patient outcomes
during stem cell transplantation with best practice and as a
platform for research. The 12 pediatric/adolescent trans-
plant centers of the UK and Ireland are increasingly
collaborative and this report summarizes the efforts of that
groups and commends them to other national pediatric
BMT groups.
Materials (or patients) and methods: The Group’s activ-
ities over the last 7 years are reviewed in the following
areas: a) National Audit Meeting in which all transplants
performed from the previous year are in a single national
meeting attended by physicians, nurses and data managers
from each center. Instructive cases and all transplant
related deaths are speciﬁcally highlighted. There have been
now 9 such annual meetings. An external auditor attends.
b) Twice yearly meetings attended by transplant centers in
which protocols are drawn up and consensus indications
discussed. c) Since 2012 there has been a national, monthly
video conference attended by transplant teams. Difﬁcult
cases referred for transplant and difﬁcult cases during
transplant are discussed. An agenda is circulated in
advance of the meeting and there is a summary of the
discussion (as meeting minutes) circulated afterwards. A
separate video MDT has been held with metabolic disease
pediatricians for particular metabolic related SCT cases. d)
The group has agreed consensus guidelines for transplant
for group members.
Results: All transplants performed in the UK have
been discussed at national audit meetings. There is a
median of 300 transplants per annum. There is a national,
annually updated, indication list for stem cell transplantation
in children for National Health Service purchasers.
National protocols for stem cell transplant in AML, ALL,
hemoglobinopathy, metabolic diseases and constitutionaland acquired aplastic anaemia. National video MDT are held
monthly and pre-HCT (75%) and post-HCT patients are
discussed. Parallel to these increasing face-to-face contacts
there is increasing email contact between the group between
meetings.
Discussion: We have found these national, increasingly
frequent joint meetings to be extremely useful and we
commend them to other national groups. We also believe
that the opportunity to discuss individual cases with
such a national group is not only helpful to patient
management but is easily seen - for families and pro-
fessionals - to be important to patient management and
generates conﬁdence in the complicated transplant
process.324
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Allogeneic HSCT remains the only curative option for pa-
tients with B-Thalassemia major. Outcome of Thalassemia
patients depends on class of Thalassemia, type of donor and
type of preparative conditioning regimen. Our objective
herein was to review the outcome of all children who
received HSCT for different types of hemoglobinopathy be-
tween the years 1998-2014 in Rambam Medical Center,
Israel.
Patients and Methods: 45 HSCT were done to 37 children,
33 Thalassemia and 4 Sickle Cell Anemia patients. Median
age at HSCT was 7.8 years (range 0.5-22 yr). Of total 33
Thalassemia patients, 25 had 1 HSCT and 8 children needed
second HSCT. 15 patients had class 1 or 2 and 18 had class 3
of Thalassemia. 38 patients received stem cells from
matched related donors, 4 from matched unrelated donors
and 3 from unrelated cord blood. Conditioning regimen
included Protocol P26 in 24 patients, 2 of them received
modiﬁed Protocol P26 with Treosulphan instead of
Busulphan; 10 patients were conditioned with protocol
Busulphan, Cyclophosphamide, with or without Anti-
tymoglobulin; 7 children had partially T-cell depleted pro-
tocol with Busulphan, Cyclophosphamide, Fludarabine and
ATG without immunosuppression after infusion of graft and
3 patients received protocol with Treosulphan, Fludarabine,
Thiotepa.
Results: Overall survival for the whole group was 88% and
event free survival 80%. 9 patients rejected the graft: 5 had
primary rejection and 4 had secondary engraftment failure
with median time of rejection 8.7 months (range 1-17
months). 2 of 9 rejected patients successfully engrafted
after second HSCT and 2-rejected second HSCT as well. 75%
of all successfully engrafted patients have full donor
chimerism, 25% mixed stable chimerism. Incidence of
acute graft versus host disease (GVHD) was 24%, grade 3-4
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chronic GVHD was 4%. 5 children died due to transplant
related mortality (TRM), all of them were class 3 Thalas-
semia; 2 patients transplanted from unrelated donor and
unrelated cord and 2 died after second HSCT. Causes of
deaths were severe infections secondary to engraftment
failure; severe hemorrhagic cystitis and multiorgan failure;
pulmonary and intracranial bleeding during engraftment
and TTP. 1 child died 3.5 years after HSCT from severe
multisystemic GVHD and complications of immunosup-
pressive therapy.
Conclusion: Our results showed that children with hemo-
globinopathy who received HSCT had excellent results with
survival above 80% despite of majority of patients with
class 3 Thalassemia and number of children who under-
went second HSCT. Factors affecting prognosis were:
advanced class of Thalassemia type of donor and second
HSCT with myeloablative regimen. Engraftment failure
continues to be a problem for Thalassemia patients. There
is a need for controlled trials to evaluate the effectiveness
of different treatment regimens for speciﬁc group of
patients.325
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Background: Hematopoietic stem cell transplant is a
curative option for a variety of non-malignant, sub-lethal
genetic diseases in children. However, the probability of
ﬁnding a suitable histocompatible sibling donor is less than
30%, especially for patients with genetic diseases, whose
siblings may also carry the affected gene. The use of
matched unrelated donors (MUD) for patients with genetic
diseases is limited by regimen related toxicity (RRT), highrates of graft failure/rejection and graft-versus-host-disease
(GVHD).
Objective: To determine if the reduced toxicity conditioning
regimen: Alemtuzmab with Busulfan, Fludarabine and
reduced dose of cyclophosphamide, would maintain
adequate immune-suppression and allow for acceptable rates
of sustained donor engraftment, low rates of RRT and GVHD.
Methods: 15 eligible patients were consented at Children’s
Hospital Los Angeles between 2007 and 2013. The condi-
tioning regimen consisted of Busulfan 16mg/kg, Alemtuzmab
52mg/m2, Fludarabine 140mg/m2and Cyclophosphamide
105mg/kg. GVHD prophylaxis consisted of Tacrolimus and
Methylprednisolone.
Results: The study population was 73.3% male with me-
dian age 7 (0.8e17.6) years old at transplant. Patients
diagnoses included HLH (n¼2), CD-40 ligand deﬁciency
(n¼2), congenital dyserythropoietic anemia (n¼2), adre-
noleukodystrophy (n¼1), Sickle Cell Disease (n¼7), Thal-
assemia (n¼1). The mean total nucleated cell count (TNC)
and CD34 dose was 5.6x108 ( 2.2x108) cells/kg and
6.4x106 ( 3.4x106) cells/kg respectively. The mean
Busulfan CSS and AUC were 888 ( 242) mg/L and 1297
( 363) mmol/L-min, respectively. The median time to
clearance of Alemtuzmab was 14 (4 to 21) days. Median
time to neutrophil engraftment and platelet engraftment
were 15 (12e28) and 25 (17e30) days respectively. One
patient had primary graft loss. Two patients had second-
ary graft loss. For 11 patients who reached and sustained
engraftment, 9 patient’s donor chimerism were more than
97% and 2 patient’s donor chimerism was 78.1% and 82%
respectively, in the most recent follow up. There were no
cases of Grade III/IV, mucositis or acute GVHD (aGVHD).
Two patients developed mild sinusoidal obstruction
syndrome (SOS). Nine patients had detectable viral reac-
tivation. Only 1 patient developed extensive cGVHD. One
patient expired due to progressive encephalopathy and
multi-organ failure. The median length of follow-up was 2
(0.2-5.4) years. The overall survival (OS) and disease free
survival (DFS) at 5 years were 93.3% and 73.3%
respectively.
Conclusion: This Alemtuzmab-based reduced toxicity
regimen appears promising with durable unrelated donor
engraftment, effective cure of clinical disease, and low rates
of RRT and GVHD. The major adverse effect was activation of
viral infections.
